- Clinical AI technology company Sensyne Health booked a full-year loss amid a rise in spending on R&D and marketing.

The company also announced that it had signed agreements with a Fortune 200 company and a data infrastructure specialist to launch and scale its digital health products under licence in the US.

Separately, it said it had entered into a formal research agreement with the UK Medicines and Healthcare products Regulatory Agency to contribute to the development of methods to validate software algorithms used in digital health.

Net losses for the year through April, including from discontinued operations, amounted to £21.9m, compared to losses of £49.8m on-year.

Pre-tax losses from continuing operations amounted to £19.0m, compared to losses of £7.1m on-year.

'I am pleased to report strong progress in our first full year reporting period as a public company, achieving a number of important milestones,' chief executive Paul Drayson said.

For the agreements in the US, the initial focus would be on taking Sensyne Health's gestational diabetes product, GDm-Health, to the US market.

Story provided by